Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balovaptan PK, Food Effect, and Esomeprazole DDI Study
NCT04156646Phase 1Completed
- Sponsor
- Roche
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of balovaptan in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Roche. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-Time Curve From Time Extrapolated to Infinity and 11 more. Started Nov 2019; status: completed.
02
Drugs
balovaptan
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04156646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156646.